At a glance
- Originator Ajinomoto
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Oct 1997 Discontinued-Preclinical for Cancer in Japan (Unknown route)
- 05 Sep 1997 New profile